1. Home
  2. SCCO vs GILD Comparison

SCCO vs GILD Comparison

Compare SCCO & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Southern Copper Corporation

SCCO

Southern Copper Corporation

HOLD

Current Price

$177.16

Market Cap

155.9B

ML Signal

HOLD

Logo Gilead Sciences Inc.

GILD

Gilead Sciences Inc.

HOLD

Current Price

$140.11

Market Cap

184.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCCO
GILD
Founded
1952
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
155.9B
184.4B
IPO Year
1996
2001

Fundamental Metrics

Financial Performance
Metric
SCCO
GILD
Price
$177.16
$140.11
Analyst Decision
Sell
Strong Buy
Analyst Count
11
18
Target Price
$135.21
$146.50
AVG Volume (30 Days)
1.7M
5.0M
Earning Date
04-24-2026
04-23-2026
Dividend Yield
2.23%
2.35%
EPS Growth
20.74
1684.21
EPS
5.24
6.78
Revenue
$6,654,500,000.00
$24,689,000,000.00
Revenue This Year
$16.76
$4.65
Revenue Next Year
N/A
$5.96
P/E Ratio
$33.94
$20.61
Revenue Growth
23.69
9.98
52 Week Low
$74.84
$95.30
52 Week High
$223.89
$157.29

Technical Indicators

Market Signals
Indicator
SCCO
GILD
Relative Strength Index (RSI) 50.52 47.28
Support Level $124.89 $108.90
Resistance Level $221.35 $149.38
Average True Range (ATR) 7.24 3.30
MACD 2.15 0.04
Stochastic Oscillator 86.25 48.48

Price Performance

Historical Comparison
SCCO
GILD

About SCCO Southern Copper Corporation

Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. It generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. The company's geographical segments are The Americas, Europe, and Asia.

About GILD Gilead Sciences Inc.

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Share on Social Networks: